FATTIZZO, BRUNO
FATTIZZO, BRUNO
Dipartimento di Oncologia ed Emato-Oncologia
Sutimlimab vs B-Cell-Targeted Therapy in Cold Agglutinin Disease: Which Is the Optimal Approach?
2026 B. Fattizzo, Y. Miyakawa, C. Broome
Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study
2026 F. Versino, M. Michel, J. Vidler, S. Payán-Pernía, R. Trikha, S.A. Gandhi, S. Gogoi, M. Wimalachandra, O. Racchi, M.T. Lupo-Stanghellini, S. Giammarco, M. Arguello Marina, M. Memoli, A. Glenthøj, G. Merati, Y.W. Wickramasinghe, A. Chitharanjan, M. Hemmer, M. Napolitano, M. Jimenez-Jambrina, F. Brioschi, A. Palma-Vallelano, T.J. Gonzalez-Lopez, C. Clissa, M. Bortolotti, G.L. Pedone, G.A. Croci, F. Passamonti, W. Barcellini, A.G. Kulasekararaj, B. Fattizzo
Thrombosis in paroxysmal nocturnal hemoglobinuria in the complement inhibitor era: mechanisms, risk stratification, and clinical management
2026 B. Fattizzo, C.Q. Schmidt
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma
2026 S. Perrone, R. Tomasello, S. Raso, O. Annibali, M. Tafuri, M. Mattana, T. Soriano, D. Fanciullo, G.M. Assanto, G.L. Pedone, E. Baldacci, E. Santacroce, U. Markovic, G. Giuffrida, M.G. Ingrascì, M. Biglietto, C. Cammarata, M. Totaro, S. Ligia, B. Fattizzo, C. Santoro, S. Siragusa, M. Napolitano
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study
2026 A.P. Iori, A. De Vivo, E. Di Bona, G. Caocci, F. Fioritoni, F. Ciceri, E. Beggiato, D. Rapezzi, A. Amendola, A. Figuera, C. Selleri, F. Longu, B. Fattizzo, A. Tucci, A. Cignetti, V. Amico, S. Sica, E. Metafuni, S. Raso, T.A. Urbano, L. Marano, N. Di Renzo, P. Spedini, A. Rambaldi, F. Lanza, C. Clissa, C. Danesin, M.B. Greve, S. Cabibbo, A. Ori, F. Cassanelli, F. Sottana, B. Campolo, G. Gasparri, F. Carini, W. Barcellini
Predicting the differential diagnosis of inherited versus acquired bone marrow failure syndromes: Development of simple clinical scoring systems
2026 M. Bortolotti, B. Fattizzo, S. Stella, J. Jiang, F. Versino, C. Engelbrecht, R. Trikha, J. Large, S. Gandhi, K. Snape, D. Consonni, F. Passamonti, W. Barcellini, A.G. Kulasekararaj
Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study
2026 F. Versino, U. Markovic, G.L. Pedone, S. Pergolizzi, F. Passamonti, W. Barcellini, A. Romano, B. Fattizzo
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience
2026 B. Fattizzo, E. Sambruna, Y. Miyakawa, M. Michel, C. Visco, M. Fillitz, G. Kannourakis, M.B. Greve, M. Kleemiss, J. Cid, A. Patriarca, L. Pavan, A. Dizdari, N. Maschio, A. Sau, C. Bitetti, R.M. Colombo, L. Curreli, D. Lame, U. Markovic, F. Pappagallo, G.L. Pedone, D. Rapezzi, V. Sammartano, N. Tumedei, A.G. Solimando, J. Marit, L. Fianchi, J. Khwaja, A. De Vivo, F. Lanza, F. Vianello, E.N. Oliva, C. Broome, F. Passamonti, U. Jaeger, B. Jilma, G. Moulis, W. Barcellini
Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia
2026 B. Fattizzo, A. Zaninoni, G.L. Pedone, M. Bortolotti, F. Passamonti, W. Barcellini
Autoimmune hemolytic anemia: New frontiers in diagnosis and therapy
2026 W. Barcellini, B. Fattizzo
Case Report: Refractory cold agglutinin disease with hypersplenism: efficacy of splenectomy in a patient treated with sutimlimab
2026 A. Sau, D. Onofrillo, A.C. Russo, G. Di Prinzio, A.M. Quaglietta, M. Di Ianni, B. Fattizzo
Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis
2026 B. Fattizzo, M. Abbatista, N. Cecchi, C. Novembrino, M. Boscolo-Anzoletti, G.L. Pedone, M. Bortolotti, A. Artoni, J.A. Giannotta, F. Peyvandi, F. Passamonti, W. Barcellini, M. Capecchi
Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World
2025 B. Fattizzo, C. Gurnari, S. Giammarco, A. Ricchiuti, H. Awada, M. Bortolotti, N. Galli, G.L. Pedone, F. Versino, D. Consonni, R. Trikha, S. Gandhi, S. Sica, J.P. Maciejewski, A. Kulasekararaj, W. Barcellini
Real‐world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study
2025 E. Metafuni, F.A. Brioschi, A. Patriarca, C. Leoni, G. Battipaglia, D. Carlino, A. Condorelli, V. Di Giacomo, S. Marktel, M.A. Marzilli, M. Miglino, E.N. Oliva, A. Sau, A. Ricco, G. Sanpaolo, A. Trolese, A.P. Iori, S. Sica, W. Barcellini, B. Fattizzo
Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
2025 A. Consagra, L. Lanino, N.H. Al Ali, L. Aguirre, Z. Xie, O. Chan, G. Andreossi, M.G. Raddi, L. Rigodanza, A. Sanna, G. Mattiuz, E. Tofacchi, C. Amato, M. Tanturli, S. De Pourcq, A. Walker, A. Kuykendall, J. Lancet, E. Padron, D.A. Sallman, F. Restuccia, A. Perego, M. Ubezio, B. Fattizzo, M. Riva, G. Maggioni, A. Campagna, M.G. Della Porta, V. Santini, R.S. Komrokji
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo-Gaucher Cells
2025 N. Scaramellini, M. Canzi, E. Cassinerio, M. Migone De Amicis, L. Pettine, B. Fattizzo, F.G. Rossi, G. Croci, I. Motta
Severe aplastic anemia secondary to immune checkpoint inhibitor: case report and literature review
2025 A. Bosi, M.C. Di Chio, M. Bortolotti, G.A. Croci, F. Passamonti, W. Barcellini, B. Fattizzo
Management of autoimmune hemolytic anemia
2025 W. Barcellini, B. Fattizzo
Bone marrow microenvironment in autoimmune hemolytic anemia: from trephine biopsy to single cell RNA sequencing
2025 B. Fattizzo, M.C. Da Via, F. Lazzaroni, A. Marchetti, A. Marella, A. Maeda, A.G. Solimando, L. Pettine, F. Passamonti, N. Bolli, W. Barcellini
Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice
2025 B. Fattizzo, F. Versino, W. Barcellini